SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models
SignaBlok presented proof-of-concept animal data on development of novel MRI contrast agent for diagnostic imaging of atherosclerosis at the 2014 Joint Annual Meeting ISMRM-ESMRMB
SignaBlok presented proof-of-concept animal data on development of a novel ligand-independent inhibitor of TREM-1 for treatment of sepsis and lung cancer at the 2014 AACR Annual Meeting
SignaBlok presented TREM-1 program in inflammation and cancer at the 2014 Inflammation, Infection and Cancer Keystone Symposium
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new nanotechnology for diagnostic imaging of atherosclerosis
